您的位置: 专家智库 > >

福建省自然科学基金(2009J01120)

作品数:2 被引量:7H指数:1
相关作者:陈增苏颖杨建伟林锦源高炜更多>>
相关机构:福建省肿瘤医院更多>>
发文基金:福建省自然科学基金福建省医学创新课题更多>>
相关领域:医药卫生更多>>

文献类型

  • 2篇中文期刊文章

领域

  • 2篇医药卫生

主题

  • 2篇多态
  • 2篇多态性
  • 2篇基因
  • 2篇基因多态性
  • 2篇CYP3A4
  • 1篇氧化酶
  • 1篇色素氧化酶
  • 1篇紫杉
  • 1篇紫杉醇
  • 1篇晚期
  • 1篇晚期胃癌
  • 1篇晚期胃癌患者
  • 1篇胃癌
  • 1篇胃癌患者
  • 1篇细胞
  • 1篇细胞色素氧化...
  • 1篇化疗
  • 1篇化疗敏感
  • 1篇含紫杉醇
  • 1篇癌患者

机构

  • 1篇福建省肿瘤医...

作者

  • 1篇蒙燕
  • 1篇高炜
  • 1篇林锦源
  • 1篇杨建伟
  • 1篇苏颖
  • 1篇陈增

传媒

  • 1篇The Ch...
  • 1篇临床与病理杂...

年份

  • 2篇2014
2 条 记 录,以下是 1-2
排序方式:
CYP3A4基因多态性与晚期胃癌患者接受紫杉醇/奥沙利铂多线化疗、化疗周期数及不良反应的相关性被引量:7
2014年
目的:应用变性高效液相色谱技术(denaturing—performanceliquidchromatography,DHPLC)高通量的实验平台,探讨晚期胃癌患者细胞色素P450代谢酶CYP3A4基因的多态性与患者接受多线化疗、化疗周期数及不良反应的相关性。方法:福建省肿瘤医院住院的接受含紫杉醇和/或奥沙利铂联合姑息化疗晚期胃癌患者外周血53份,进行全血DNA分离、提取,经PCR,DHPLC分析筛查以及DNA测序鉴定基因型,观察并评价患者接受多线化疗、化疗周期数及不良反应与CYP3A4多态性的相关性。结果:53例进展期胃癌患者CYP3A4经DHPLC筛查,单峰者f野生型)32例,双峰者(突变型)21例。测序结果显示双峰者CYP3A4第10号外显子上27位c的缺失突变。单峰组接受一线治疗15例,二线治疗10例,二线以上治疗8例,其中3例为三线以上治疗;平均化疗周期数为8.2周期,中位总生存时问为13.0个月(95%CI:7.092~18.908个月)。双峰组接受一线治疗10例,二线治疗8例,二线以上治疗3例,平均化疗8.7周期,中位总生存时间为14.0个月(95%CI:7.555~20.445个月)。两组中位总生存时间比较差异无统计学意义(P=0.326)。野生型组较突变型组不良反应发生率低,在3~4级毒副作用方面较为明显,结论:CYP3A4突变型者第10号外显子上第27位C缺失;该基因多态性与化疗不良反应相关,尚不能作为疗效的预测指标。
杨建伟苏颖陈增蒙燕高炜林锦源
关键词:DHPLCCYP3A4基因多态性晚期胃癌
胃癌细胞色素氧化酶CYP3A4基因多态性与含紫杉醇方案化疗敏感相关性的研究(英文)
2014年
Objective: The aim of the study was to investigate the relationship between susceptibility of paclitaxel-based regimen and gene polymorphisms of cytochrome oxidase CYP3A4 for advanced gastric cancer. Methods: Peripheral venous blood sample of 53 advanced gastric cancer patients were enrolled to test the mutation of CYP3A4 gene by denaturing high performance liquid chromatography(DHPLC) and DNA sequencing. The relation between the efficacy of paclitaxel-based regimen and CYP3A4 gene polymorphisms was further analyzed. Results: DHPLC indicated that among the 53 patients, 21 cases showed biomodal type(mutation) and 32 cases were of unimodal type(wild-type). Sequencing results showed that the deletion mutation was found at the 27 th basic group of C in exon 10 of CYP3A4 gene. The response rate(RR) and disease control rate(DCR) of wild-type group were 40.6% and 84.4%, while in mutation group they were 33.3% and 85.7%, respectively, with no significances between the two groups(P > 0.05). Of all 53 cases, the median progression-free survival(PFS) was 6.5 months(95% CI: 3.576–9.424 months), and the median overall survival(OS) was 11.0 months(95% CI: 6.955–15.045 months). The median PFS and OS in wild-type group had no differences compared with those in mutation group(7.0 months vs. 7.0 months, P > 0.05; 10.0 months vs. 14.0 months, P > 0.05). Between wild-type and mutation groups, the median PFS of patients applied with oxaliplatin containing regimen and the median OS in patients applied with/without oxaliplatin had no significant differences(P > 0.05), while the median PFS in patients received non-oxaliplatin regime had statistical differences(P = 0.024). The median PFS and OS in patients receiving 3-drug or 2-drug regimes had no correlation with CYP3A4 gene polymorphisms. The adverse effects in the two groups were mild, mainly in grades 1–2. The common adverse effects were anorexia, nausea/vomiting and leucopenia. Conclusion: Deletion mutation was located in the 27 th basic group of C in exon 10 of CYP3A4 gene. P
Jianwei YangYan MengYing SuZeng ChenWei GaoJinyuan LinJing JiaHuamei Lin
关键词:细胞色素氧化酶紫杉醇基因多态性
共1页<1>
聚类工具0